vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and STIFEL FINANCIAL CORP (SF). Click either name above to swap in a different company.
STIFEL FINANCIAL CORP is the larger business by last-quarter revenue ($1.1B vs $814.3M, roughly 1.4× Amneal Pharmaceuticals, Inc.). STIFEL FINANCIAL CORP runs the higher net margin — 23.5% vs 4.3%, a 19.2% gap on every dollar of revenue. On growth, STIFEL FINANCIAL CORP posted the faster year-over-year revenue change (23.0% vs 11.5%). STIFEL FINANCIAL CORP produced more free cash flow last quarter ($369.0M vs $108.5M). Over the past eight quarters, STIFEL FINANCIAL CORP's revenue compounded faster (21.1% CAGR vs 11.1%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Stifel Financial Corp. is an American multinational independent investment bank and financial services company created under the Stifel name in July 1983 and listed on the New York Stock Exchange on November 24, 1986. Its predecessor company was founded in 1890 as the Altheimer and Rawlings Investment Company and is headquartered in downtown St. Louis, Missouri.
AMRX vs SF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $814.3M | $1.1B |
| Net Profit | $35.1M | $264.4M |
| Gross Margin | 36.5% | — |
| Operating Margin | 13.8% | 27.3% |
| Net Margin | 4.3% | 23.5% |
| Revenue YoY | 11.5% | 23.0% |
| Net Profit YoY | 212.9% | 8.3% |
| EPS (diluted) | $0.10 | $2.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $814.3M | $1.1B | ||
| Q3 25 | $784.5M | $962.6M | ||
| Q2 25 | $724.5M | $838.9M | ||
| Q1 25 | $695.4M | $842.5M | ||
| Q4 24 | $730.5M | $916.0M | ||
| Q3 24 | $702.5M | $810.9M | ||
| Q2 24 | $701.8M | $798.9M | ||
| Q1 24 | $659.2M | $768.1M |
| Q4 25 | $35.1M | $264.4M | ||
| Q3 25 | $2.4M | $211.4M | ||
| Q2 25 | $22.4M | $155.1M | ||
| Q1 25 | $12.2M | $53.0M | ||
| Q4 24 | $-31.1M | $244.0M | ||
| Q3 24 | $-156.0K | $158.5M | ||
| Q2 24 | $6.0M | $165.3M | ||
| Q1 24 | $-91.6M | $163.6M |
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 36.1% | — |
| Q4 25 | 13.8% | 27.3% | ||
| Q3 25 | 9.0% | 29.7% | ||
| Q2 25 | 15.4% | 25.5% | ||
| Q1 25 | 14.4% | 7.5% | ||
| Q4 24 | 10.4% | 29.1% | ||
| Q3 24 | 12.6% | 26.7% | ||
| Q2 24 | 13.6% | 28.4% | ||
| Q1 24 | -1.6% | 28.5% |
| Q4 25 | 4.3% | 23.5% | ||
| Q3 25 | 0.3% | 22.0% | ||
| Q2 25 | 3.1% | 18.5% | ||
| Q1 25 | 1.8% | 6.3% | ||
| Q4 24 | -4.3% | 26.6% | ||
| Q3 24 | -0.0% | 19.5% | ||
| Q2 24 | 0.9% | 20.7% | ||
| Q1 24 | -13.9% | 21.3% |
| Q4 25 | $0.10 | $2.30 | ||
| Q3 25 | $0.01 | $1.84 | ||
| Q2 25 | $0.07 | $1.34 | ||
| Q1 25 | $0.04 | $0.39 | ||
| Q4 24 | $-0.10 | $2.10 | ||
| Q3 24 | $0.00 | $1.34 | ||
| Q2 24 | $0.02 | $1.41 | ||
| Q1 24 | $-0.30 | $1.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.0M | $2.3B |
| Total DebtLower is stronger | $2.6B | $617.4M |
| Stockholders' EquityBook value | $-70.8M | $6.0B |
| Total Assets | $3.7B | $41.3B |
| Debt / EquityLower = less leverage | — | 0.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.0M | $2.3B | ||
| Q3 25 | $201.2M | $3.2B | ||
| Q2 25 | $71.5M | $1.9B | ||
| Q1 25 | $59.2M | $2.7B | ||
| Q4 24 | $110.6M | $2.6B | ||
| Q3 24 | $74.0M | $1.9B | ||
| Q2 24 | $43.8M | $2.6B | ||
| Q1 24 | $46.5M | $3.4B |
| Q4 25 | $2.6B | $617.4M | ||
| Q3 25 | $2.6B | $617.2M | ||
| Q2 25 | $2.2B | $617.0M | ||
| Q1 25 | $2.2B | $616.8M | ||
| Q4 24 | $2.4B | $616.6M | ||
| Q3 24 | $2.4B | $616.4M | ||
| Q2 24 | $2.4B | $1.1B | ||
| Q1 24 | $2.4B | $1.1B |
| Q4 25 | $-70.8M | $6.0B | ||
| Q3 25 | $-109.5M | $5.8B | ||
| Q2 25 | $-112.1M | $5.6B | ||
| Q1 25 | $-131.7M | $5.5B | ||
| Q4 24 | $-109.3M | $5.7B | ||
| Q3 24 | $-93.4M | $5.6B | ||
| Q2 24 | $-57.5M | $5.4B | ||
| Q1 24 | $-63.7M | $5.3B |
| Q4 25 | $3.7B | $41.3B | ||
| Q3 25 | $3.6B | $41.7B | ||
| Q2 25 | $3.4B | $39.9B | ||
| Q1 25 | $3.4B | $40.4B | ||
| Q4 24 | $3.5B | $39.9B | ||
| Q3 24 | $3.5B | $38.9B | ||
| Q2 24 | $3.5B | $37.8B | ||
| Q1 24 | $3.5B | $38.3B |
| Q4 25 | — | 0.10× | ||
| Q3 25 | — | 0.11× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.21× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $130.3M | $382.4M |
| Free Cash FlowOCF − Capex | $108.5M | $369.0M |
| FCF MarginFCF / Revenue | 13.3% | 32.7% |
| Capex IntensityCapex / Revenue | 2.7% | 1.2% |
| Cash ConversionOCF / Net Profit | 3.72× | 1.45× |
| TTM Free Cash FlowTrailing 4 quarters | $269.9M | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $130.3M | $382.4M | ||
| Q3 25 | $118.5M | $338.3M | ||
| Q2 25 | $83.8M | $607.5M | ||
| Q1 25 | $7.4M | $-211.2M | ||
| Q4 24 | $118.1M | $694.6M | ||
| Q3 24 | $141.8M | $198.3M | ||
| Q2 24 | $39.7M | $207.2M | ||
| Q1 24 | $-4.4M | $-609.7M |
| Q4 25 | $108.5M | $369.0M | ||
| Q3 25 | $106.2M | $321.1M | ||
| Q2 25 | $61.0M | $592.7M | ||
| Q1 25 | $-5.8M | $-227.8M | ||
| Q4 24 | $102.9M | $677.2M | ||
| Q3 24 | $124.8M | $185.6M | ||
| Q2 24 | $29.0M | $173.3M | ||
| Q1 24 | $-13.6M | $-619.4M |
| Q4 25 | 13.3% | 32.7% | ||
| Q3 25 | 13.5% | 33.4% | ||
| Q2 25 | 8.4% | 70.6% | ||
| Q1 25 | -0.8% | -27.0% | ||
| Q4 24 | 14.1% | 73.9% | ||
| Q3 24 | 17.8% | 22.9% | ||
| Q2 24 | 4.1% | 21.7% | ||
| Q1 24 | -2.1% | -80.6% |
| Q4 25 | 2.7% | 1.2% | ||
| Q3 25 | 1.6% | 1.8% | ||
| Q2 25 | 3.2% | 1.8% | ||
| Q1 25 | 1.9% | 2.0% | ||
| Q4 24 | 2.1% | 1.9% | ||
| Q3 24 | 2.4% | 1.6% | ||
| Q2 24 | 1.5% | 4.2% | ||
| Q1 24 | 1.4% | 1.3% |
| Q4 25 | 3.72× | 1.45× | ||
| Q3 25 | 50.00× | 1.60× | ||
| Q2 25 | 3.74× | 3.92× | ||
| Q1 25 | 0.61× | -3.99× | ||
| Q4 24 | — | 2.85× | ||
| Q3 24 | — | 1.25× | ||
| Q2 24 | 6.62× | 1.25× | ||
| Q1 24 | — | -3.73× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
SF
Segment breakdown not available.
